1. Home
  2. RSF vs ELOX Comparison

RSF vs ELOX Comparison

Compare RSF & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RiverNorth Capital and Income Fund

RSF

RiverNorth Capital and Income Fund

SELL

Current Price

$14.06

Market Cap

58.6M

Sector

Finance

ML Signal

SELL

Logo Eloxx Pharmaceuticals Inc. Common Stock

ELOX

Eloxx Pharmaceuticals Inc. Common Stock

N/A

Current Price

$11.89

Market Cap

52.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
RSF
ELOX
Founded
2016
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
58.6M
52.5M
IPO Year
2015
2013

Fundamental Metrics

Financial Performance
Metric
RSF
ELOX
Price
$14.06
$11.89
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $37.50
AVG Volume (30 Days)
6.3K
★ 18.8K
Earning Date
01-01-0001
11-16-2026
Dividend Yield
★ 10.61%
N/A
EPS Growth
N/A
★ 41.67
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$14.04
$10.00
52 Week High
$15.07
$23.40

Technical Indicators

Market Signals
Indicator
RSF
ELOX
Relative Strength Index (RSI) 36.21 43.67
Support Level N/A $12.47
Resistance Level $14.70 $14.65
Average True Range (ATR) 0.10 1.00
MACD -0.00 0.09
Stochastic Oscillator 17.65 48.37

Price Performance

Historical Comparison
RSF
ELOX

About RSF RiverNorth Capital and Income Fund

RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.

About ELOX Eloxx Pharmaceuticals Inc. Common Stock

Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.

Share on Social Networks: